GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

截至2025年1月，卡替拉韦长效方案是国内首个且唯一获国家药监局批准上市的用于HIV暴露前预防的长效注射针剂。作为一种HIV-1整合酶链转移抑制剂 (INSTI)，卡替拉韦长效方案仅需每年注射最少6次即可实现HIV暴露前预防。使用者将在前两个月内接受每月600mg (3ml)的起始注射，随后每两个月接受一次600mg (3ml)的继续注射。

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

A HUGE study that has been launched to find treatments for diseases by measuring how the proteins circulating in our bodies ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company ...

1 According to Yale Medicine, approximately 50% to 60% of all GISTs are located in the stomach, with 30% to 35% of all cases located in the small intestine and 5% in the colon and rectum. Only 1% of ...

British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is producing ...